Revenio: Cautiously re-boarding the train
We raise Revenio's recommendation from Reduce to Accumulate, but reduce our target price. The forecasts were under pressure from weaker-than-expected short-term growth outlook of tonometers, and we had to take a breather with the expectations of the HOME2 product. Imaging devices retain their excellent outlook. Despite the decrease in share price, the valuation (2023e P/E 45x) is very high, but the multiples are gradually normalizing with strong earnings growth, Confidence in the company’s value creation exceeds the concern about valuation risk, so we will return very cautiously to the company's growth story.
Revenio Group
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures21.10.2021
2020 | 21e | 22e | |
---|---|---|---|
Revenue | 61.1 | 77.7 | 97.6 |
growth-% | 23.41 % | 27.29 % | 25.53 % |
EBIT (adj.) | 19.2 | 23.6 | 31.9 |
EBIT-% (adj.) | 31.44 % | 30.40 % | 32.66 % |
EPS (adj.) | 0.58 | 0.71 | 0.93 |
Dividend | 0.32 | 0.38 | 0.52 |
Dividend % | 0.64 % | 1.41 % | 1.93 % |
P/E (adj.) | 86.56 | 37.66 | 28.80 |
EV/EBITDA | 61.53 | 28.98 | 20.89 |